Tim Lugo
Stock Analyst at William Blair
(0.50)
# 4,165
Out of 5,172 analysts
22
Total ratings
35.71%
Success rate
-25.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $0.61 | - | 4 | Dec 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $54.13 | - | 3 | Oct 30, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $10.48 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $7.03 | +468.99% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $9.23 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $205.07 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $3.69 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $26.84 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $8.17 | - | 2 | Sep 20, 2023 | |
| AVIR Atea Pharmaceuticals | Initiates: Outperform | n/a | $5.66 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.94 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.13 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.62 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $8.93 | +415.12% | 1 | May 30, 2017 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.61
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $54.13
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.48
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $7.03
Upside: +468.99%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.23
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $205.07
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.69
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $26.84
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.17
Upside: -
Atea Pharmaceuticals
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.66
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $54.94
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $0.13
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.62
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $8.93
Upside: +415.12%